Urinary Tract Infection — Intravaginal LACTIN-V for Prevention of Recurrent Urinary Tract Infection
Citation(s)
Antonio MA, Hawes SE, Hillier SL The identification of vaginal Lactobacillus species and the demographic and microbiologic characteristics of women colonized by these species. J Infect Dis. 1999 Dec;180(6):1950-6. doi: 10.1086/315109.
Antonio MA, Hillier SL DNA fingerprinting of Lactobacillus crispatus strain CTV-05 by repetitive element sequence-based PCR analysis in a pilot study of vaginal colonization. J Clin Microbiol. 2003 May;41(5):1881-7. doi: 10.1128/JCM.41.5.1881-1887.2003.
Gupta K, Scholes D, Stamm WE Increasing prevalence of antimicrobial resistance among uropathogens causing acute uncomplicated cystitis in women. JAMA. 1999 Feb 24;281(8):736-8. doi: 10.1001/jama.281.8.736.
Gupta K, Stapleton AE, Hooton TM, Roberts PL, Fennell CL, Stamm WE Inverse association of H2O2-producing lactobacilli and vaginal Escherichia coli colonization in women with recurrent urinary tract infections. J Infect Dis. 1998 Aug;178(2):446-50. doi: 10.1086/515635.
Hooton TM, Roberts PL, Stamm WE Effects of recent sexual activity and use of a diaphragm on the vaginal microflora. Clin Infect Dis. 1994 Aug;19(2):274-8. doi: 10.1093/clinids/19.2.274.
Osset J, Bartolome RM, Garcia E, Andreu A Assessment of the capacity of Lactobacillus to inhibit the growth of uropathogens and block their adhesion to vaginal epithelial cells. J Infect Dis. 2001 Feb 1;183(3):485-91. doi: 10.1086/318070. Epub 2000 Dec 29.
Stamey TA, Sexton CC The role of vaginal colonization with enterobacteriaceae in recurrent urinary infections. J Urol. 1975 Feb;113(2):214-7. doi: 10.1016/s0022-5347(17)59447-1.
Interventional studies are often prospective and are specifically tailored to evaluate direct impacts of treatment or preventive measures on disease.
Observational studies are often retrospective and are used to assess potential causation in exposure-outcome relationships and therefore influence preventive methods.
Expanded access is a means by which manufacturers make investigational new drugs available, under certain circumstances, to treat a patient(s) with a serious disease or condition who cannot participate in a controlled clinical trial.
Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.
Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.
